Arriving in the field of obesity management, retatrutide presents a different strategy. Different from many existing medications, retatrutide operates as a dual agonist, concurrently affecting both glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP) receptors. The dual stimulation fosters various beneficial effect